| Home | E-Submission | Sitemap | Contact Us |  
Korean J Med > Volume 87(4); 2014 > Article
The Korean Journal of Medicine 2014;87(4): 496-500.
Azacitidine 치료 후 폐 손상이 발생한 골수형성이상증후군 1예
김호철, 김상형, 안지환, 권혜미, 최종한, 김태형, 이제환
울산대학교 의과대학 내과학교실
Azacitidine-Induced Lung Injury in a Patient with Myelodysplastic Syndrome
Ho Cheol Kim, Sang Hyung Kim, Jee Hwan Ahn, Hye Mi Kwon, Jong Han Choi, Tae Hyung Kim, Je-Hwan Lee
Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea
Corresponding Author: Je-Hwan Lee ,Tel: +82-2-3010-3218, Fax: +82-2-3010-6885, Email: jhlee3@amc.seoul.kr
Received: November 3, 2013;   Revised: December 27, 2013;   Accepted: January 9, 2014.
This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial License (http://creativecommons.org/licenses/bync/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
In randomized phase 3 clinical trials azacitidine has been shown to prolong survival in patients with higher-risk myelodysplastic syndrome (MDS). Therefore, azacitidine therapy should be considered for treating MDS patients with higher-risk disease. A 78- year-old male was administered the first cycle of azacitidine treatment for higher-risk MDS. On day three of chemotherapy he complained of fever and dyspnea, and radiographic findings revealed bilateral perihilar-peribronchial infiltration and a small amount of pleural effusion. Considering the possibility of pneumonia, intravenous broad-spectrum antibiotics were administered and azacitidine therapy was discontinued. Upon improvement of the patient’s subjective symptoms and radiographic abnormalities, azacitidine therapy was resumed. However, fever and dyspnea developed again upon recommencement of azacitidine therapy. A diagnosis was made of azacitidine-induced lung injury and corticosteroid treatment was administered. Although lung injury is a rare complication induced by azacitidine, physicians should be aware of this life-threatening side effect.
Keywords: Myelodysplastic Syndrome; Azacitidine; Lung injury
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community